What's in your wallet? Probably less money than you started July with if you own Capital One stock. Find out why shares of Capital One tanked in July, and whether a rebound can be expected.
A history of stellar management, a successful switch into direct-to-consumer sales, and strategically profitable investments in R&D and marketing are all traits that keep Nike ahead of the pack.
Merck's Q2 results topped Wall Street's expectations, but its headline figures don't tell the full story.
Pfizer knocked it out of the ballpark in Q2, but you probably missed these three important points if you were enamored with the headline figures.
Big Pharma Merck is scheduled to report its second-quarter earnings results on July 28. Here are three questions investors are expecting to have answered on that date.
Big Pharma Pfizer is on deck with its Q2 earnings results. See what questions and concerns Wall Street and investors expect Pfizer to address.
It's true that the broad-based S&P 500 has more than tripled since March 2009, but there are still plenty of enticing value stocks worth considering if you're willing to do some digging.
Big Pharma companies are truly in a class of their own. Here are seven facts about the industry you may not be aware of.
Johnson & Johnson kicks off earnings season for the pharmaceutical sector and answers some very important questions and concerns in the process.
ExxonMobil has looked bleak for a while, and shares have plunged. Which begs the question, has the price fallen low enough to warrant plunging in for some deep value, or is Exxon more of a value trap?